Results 11 to 20 of about 1,717 (156)
Hospital Pharmacy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +2 more sources
Journal of Pharmaceutical Health Care and Sciences, 2023 Background Tedizolid is an oxazolidinone anti-MRSA drug with included in the National Health Insurance Drug Price List in 2018. The effect of hemodialysis on tedizolid phosphate concentrations has been reported; pre-dialysis concentrations decreased by ...
Satoshi Yoshikawa +3 more
doaj +1 more source
Safety and tolerability of tedizolid as oral treatment for bone and joint infections
Microbiology Spectrum, 2023 Bone and joint infections (BJIs) are common infections increasingly managed with oral therapy. However, there are limited safe oral options for many Gram-positive pathogens.
Loren G. Miller +10 more
doaj +1 more source
Antibiotics, 2021 Tedizolid and linezolid have antibacterial activity against the most important acute bacterial skin and skin-structure infection (ABSSSIs) pathogens.
Alicia Rodríguez-Gascón +3 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2022 Objectives: The aim of this study is to compare the in vitro activity and minimal inhibitory concentration (MIC) distributions of tedizolid and linezolid against Mycobacterium avium complex (MAC) strains using a reference broth microdilution assay and a ...
Eduardo Marfil +3 more
doaj +1 more source
Tedizolid: new data and experiences for clinical practice [PDF]
Revista Española de Quimioterapia, 2021 The most relevant information on the clinical uses of tedizolid from studies published in the last 18 months is presented in this brief review. The most important data indicate better tolerance and safety profile of long-term therapeutic regimes in off-label indications, such as osteoarticular infections and those caused by mycobacteria. Its lower risk
Salavert Lleti, M +3 more
openaire +3 more sources
Brazilian Journal of Infectious Diseases, 2016 Acute bacterial skin and skin structure infections are caused mainly by Gram-positive bacteria which are often treated with intravenous vancomycin, daptomycin, or linezolid, with potential step down to oral linezolid for outpatients.
Alejandro Ortiz-Covarrubias +9 more
doaj +1 more source
International Journal of Infectious Diseases, 2021 Objectives: The antimicrobial activity of tedizolid and comparators was evaluated against a large worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae isolates recovered from patients with pneumonia.
Cecilia G. Carvalhaes +3 more
doaj +1 more source
Thrombocytopenia with Tedizolid and Linezolid [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Several studies have suggested the risk of thrombocytopenia with tedizolid, a second-in-class oxazolidinone antibiotic (approved June 2014), is less than that observed with linezolid (first-in-class oxazolidinone). Using data from the Food and Drug Administration adverse event reporting system (July 2014 through December 2016), we ...
Lee, Erica Yookyung, Caffrey, R
openaire +3 more sources
Tedizolid Phosphate: a Next-Generation Oxazolidinone [PDF]
Infectious Diseases and Therapy, 2015 Treatment of multidrug-resistant Gram-positive infections continues to challenge clinicians as the emergence of new resistance mechanisms outpaces introduction of novel antimicrobial agents. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus
Rybak, Jeffrey M., Roberts, Karrine
openaire +2 more sources